Zealand Pharma A/S

ZEAL

N/A

NASDAQHealthcare🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Apr 2, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

4 upcoming, 0 past

Phase 2Next

Petrelintide Phase 2 Results Expected

Apr 2, 2026Petrelintide221

Primary completion for Petrelintide trial (NCT06926842) in Overweight

Source

⭐Phase 3

glepaglutide Phase 3 Results Expected

April 2026~Glepaglutide145

Primary completion for glepaglutide trial (NCT03905707) in Short Bowel Syndrome

Source

Phase 2

Petrelintide Phase 2 Results Expected

Aug 13, 2026Petrelintide221

Primary completion for Petrelintide trial (NCT06926842) in Overweight

Source

⭐Phase 3

glepaglutide Phase 3 Results Expected

Oct 31, 2026Glepaglutide145

Primary completion for glepaglutide trial (NCT03905707) in Short Bowel Syndrome

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

GlucaGen

Phase 3

Hypoglycemia

Glepaglutide

Phase 3

Short Bowel Syndrome

dasiglucagon

Phase 3

Hypoglycemia

ZP1848

Phase 2

Short Bowel Syndrome

ZP4207

Phase 2

Hypoglycemia

ZP4207(dasiglucagon) glucagon analogue

Phase 2

Diabetes Mellitus Type 1

Petrelintide

Phase 2

Obesity

danegaptide

Phase 2

Focus of Study is STEMI

Drug Name	Phase	Indication	Designations
GlucaGen	Phase 3	Hypoglycemia	-
Glepaglutide	Phase 3	Short Bowel Syndrome	-
dasiglucagon	Phase 3	Hypoglycemia	-
ZP1848	Phase 2	Short Bowel Syndrome	-
ZP4207	Phase 2	Hypoglycemia	-
ZP4207(dasiglucagon) glucagon analogue	Phase 2	Diabetes Mellitus Type 1	-
Petrelintide	Phase 2	Obesity	-
danegaptide	Phase 2	Focus of Study is STEMI	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

ZEAL News